v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
OPERATING EXPENSES        
Research and development expenses $ 14,359 $ 72,720 $ 79,196 $ 161,270
Acquired in-process research and development expense 1,500,000 1,500,000
General and administrative expenses 355,536 327,177 1,029,155 1,080,438
Total operating expenses 1,869,895 399,897 2,608,351 1,241,708
LOSS FROM OPERATIONS (1,869,895) (399,897) (2,608,351) (1,241,708)
NET LOSS $ (1,869,895) $ (399,897) $ (2,608,351) $ (1,241,708)
Net loss per share attributable to common stockholders, basic $ (0.12) $ (0.02) $ (0.16) $ (0.08)
Net loss per share attributable to common stockholders, diluted $ (0.12) $ (0.02) $ (0.16) $ (0.08)
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, basic 16,072,267 16,072,267 16,072,267 14,950,840
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, diluted 16,072,267 16,072,267 16,072,267 14,950,840